BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 17.7] [Reference Citation Analysis]
Number Citing Articles
1 Kabir T, Syn NL, Guo Y, Lim KI, Goh BKP. Laparoscopic liver resection for huge (≥10 cm) hepatocellular carcinoma: A coarsened exact-matched single-surgeon study. Surg Oncol 2021;37:101569. [PMID: 33839442 DOI: 10.1016/j.suronc.2021.101569] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Molinari M, Kaltenmeier C, Samra P, Liu H, Wessel C, Lou Klem M, Dharmayan S, Emmanuel B, Al Harakeh H, Tohme S, Geller D, Tevar A, Hughes CB, Humar A, Bataller R, Behari J. Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 7226 Patients. Annals of Surgery Open 2021;2:e065. [DOI: 10.1097/as9.0000000000000065] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fteah AM, Ahmed AI, Mosaad NA, Hassan MM, Mahmoud SH. Association of MicroRNA 196a and 499 Polymorphisms with Development of Cirrhosis and Hepatocellular Carcinoma Post-HCV Infection in Egyptian Patients. Asian Pac J Cancer Prev 2019;20:3479-85. [PMID: 31759375 DOI: 10.31557/APJCP.2019.20.11.3479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Liu DM, Leung TW, Chow PK, Ng DC, Lee RC, Kim YH, Mao Y, Cheng YF, Teng GJ, Lau WY. Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia. Int J Surg 2022;102:106094. [PMID: 35662438 DOI: 10.1016/j.ijsu.2021.106094] [Reference Citation Analysis]
5 Di H, Mi Z, Sun Y, Liu X, Liu X, Li A, Jiang Y, Gao H, Rong P, Liu D. Nanozyme-assisted sensitive profiling of exosomal proteins for rapid cancer diagnosis. Theranostics 2020;10:9303-14. [PMID: 32802193 DOI: 10.7150/thno.46568] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
6 Rizk M, Guilloteau A, Mouillot T, Thiefin G, Bronowicki JP, Richou C, Doffoel M, Diab Assaf M, Hillon P, Cottet V. Dietary components modulate the risk of hepatocellular carcinoma in cirrhotic patients. Nutr Res 2019;61:82-94. [PMID: 30683441 DOI: 10.1016/j.nutres.2018.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu S, Qiu J, He G, Geng C, He W, Liu C, Cai D, Pan H, Tian Q. Dermatopontin inhibits WNT signaling pathway via CXXC finger protein 4 in hepatocellular carcinoma. J Cancer 2020;11:6288-98. [PMID: 33033513 DOI: 10.7150/jca.47157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Bakopoulos A, Koliakos N, Tsilimigras DI, Schizas D, Moris D, Angelopoulos A, Spanakos S, Spartalis E, Patapis P, Skandalakis P, Troupis T. Management of ruptured liver segment IV hepatocellular carcinoma: is transarterial embolization (TAE) superior to chemoembolization (TACE)?-the jury is still out. Ann Transl Med 2018;6:272. [PMID: 30094258 DOI: 10.21037/atm.2018.06.01] [Reference Citation Analysis]
9 Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X, Calvisi DF. Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. Front Oncol 2019;9:1412. [PMID: 31921669 DOI: 10.3389/fonc.2019.01412] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
10 Wang W, Wang Y, Liu M, Zhang Y, Yang T, Li D, Huang Y, Li Q, Bai G, Shi L. Betulinic acid induces apoptosis and suppresses metastasis in hepatocellular carcinoma cell lines in vitro and in vivo. J Cell Mol Med 2019;23:586-95. [PMID: 30417527 DOI: 10.1111/jcmm.13964] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
11 Lopez-Lopez V, Brusadin R, López-Conesa A, Capel A, Navarro-Barrios Á, Cayuela V, Lopez-Banet E, Garzón-Arana A, Parrilla-Paricio P, Robles-Campos R. Preoperative transarterial chemoembolization for laparoscopic liver resection in Child A cirrhotic patients with hepatocellular carcinoma. Langenbecks Arch Surg 2021;406:763-71. [PMID: 33411038 DOI: 10.1007/s00423-020-02056-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jiang L, Stärkel P, Fan JG, Fouts DE, Bacher P, Schnabl B. The gut mycobiome: a novel player in chronic liver diseases. J Gastroenterol 2021;56:1-11. [PMID: 33151407 DOI: 10.1007/s00535-020-01740-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
13 Chua DW, Koh YX, Liew YX, Chan CY, Lee SY, Cheow PC, Chow PK, Chung AY, Ooi LL, Goh BK. Pre-operative predictors of early recurrence/mortality including the role of inflammatory indices in patients undergoing partial hepatectomy for spontaneously ruptured hepatocellular carcinoma. J Surg Oncol 2018;118:1227-36. [PMID: 30399204 DOI: 10.1002/jso.25281] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Mohan R, Kabir T, Wu AGR, Lim KI, Goh BKP. Analysis of perioperative outcomes following laparoscopic repeat liver resection compared to laparoscopic primary liver resection based on a single surgeon's experience: A 1:2 propensity score-matched study. Surg Oncol 2020;35:382-7. [PMID: 33035786 DOI: 10.1016/j.suronc.2020.09.020] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Tran NH. Shifting Epidemiology of Hepatocellular Carcinoma in Far Eastern and Southeast Asian Patients: Explanations and Implications. Curr Oncol Rep. [DOI: 10.1007/s11912-021-01160-5] [Reference Citation Analysis]
16 Park S, Rim CH, Jung YK, Yoon WS. Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. Can J Gastroenterol Hepatol 2021;2021:6640121. [PMID: 33505941 DOI: 10.1155/2021/6640121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Cheng L, Jain D, Kakar S, Torbenson MS, Wu TT, Yeh MM. Hepatocellular neoplasms arising in genetic metabolic disorders: steatosis is common in both the tumor and background liver. Hum Pathol 2021;108:93-9. [PMID: 33245984 DOI: 10.1016/j.humpath.2020.11.012] [Reference Citation Analysis]
18 Yang D, Zhuang B, Wang Y, Xie X, Xie X. Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis. BMC Gastroenterol 2020;20:402. [PMID: 33246417 DOI: 10.1186/s12876-020-01544-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Kemp L, Clare KE, Brennan PN, Dillon JF. New horizons in hepatitis B and C in the older adult. Age Ageing 2019;48:32-7. [PMID: 30379991 DOI: 10.1093/ageing/afy170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Wu J, Liu S, Xiang Y, Qu X, Xie Y, Zhang X. Bioinformatic Analysis of Circular RNA-Associated ceRNA Network Associated with Hepatocellular Carcinoma. Biomed Res Int 2019;2019:8308694. [PMID: 31886256 DOI: 10.1155/2019/8308694] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
21 Liu C, Yang S, Wang K, Bao X, Liu Y, Zhou S, Liu H, Qiu Y, Wang T, Yu H. Alkaloids from Traditional Chinese Medicine against hepatocellular carcinoma. Biomed Pharmacother 2019;120:109543. [PMID: 31655311 DOI: 10.1016/j.biopha.2019.109543] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
22 Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol 2020;50:1370-9. [PMID: 32719873 DOI: 10.1093/jjco/hyaa130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
23 Wei CY, Chau GY, Chen PH, Liu CA, Huang YH, Huo TI, Hou MC, Lin HC, Su YH, Wu JC, Su CW. A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. Sci Rep 2020;10:17259. [PMID: 33057213 DOI: 10.1038/s41598-020-74424-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, Negri E. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302-309. [PMID: 28336466 DOI: 10.1016/j.jhep.2017.03.011] [Cited by in Crossref: 271] [Cited by in F6Publishing: 281] [Article Influence: 54.2] [Reference Citation Analysis]
25 Yoon SM. External Beam Radiotherapy for Hepatocellular Carcinoma: a Review of the Current Guidelines in the East and the West. J Liver Cancer 2021;21:25-33. [DOI: 10.17998/jlc.21.1.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Gavriilidis P, Roberts KJ, Askari A, Sutcliffe RP, Huo TL, Liu PH, Hidalgo E, Compagnon P, Lim C, Azoulay D. Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. J Hepatol. 2017;67:991-998. [PMID: 28690176 DOI: 10.1016/j.jhep.2017.06.028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
27 Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Bräu N; Liver Cancer in HIV and ITA.LI.CA Study Groups. Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. J Clin Oncol 2019;37:296-304. [PMID: 30562130 DOI: 10.1200/JCO.18.00885] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
28 Zhu F, Wang BR, Zhu ZF, Wang SQ, Chai CX, Shang D, Li M. Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma? World J Gastrointest Surg 2021; 13(12): 1523-1535 [DOI: 10.4240/wjgs.v13.i12.1523] [Reference Citation Analysis]
29 Xu Y, Guo Q, Wei L. The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5096. [PMID: 34680245 DOI: 10.3390/cancers13205096] [Reference Citation Analysis]
30 Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018. Korean J Radiol 2021;22:1066-76. [PMID: 33739633 DOI: 10.3348/kjr.2020.0846] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Zhang D. Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma. Immuno-Oncology Technology 2020;7:1. [DOI: 10.1016/j.iotech.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wu G, Ju X, Wang Y, Li Z, Gan X. Up-regulation of SNHG6 activates SERPINH1 expression by competitive binding to miR-139-5p to promote hepatocellular carcinoma progression. Cell Cycle 2019;18:1849-67. [PMID: 31258024 DOI: 10.1080/15384101.2019.1629772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
33 Yassin NYS, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomed Pharmacother 2021;145:112409. [PMID: 34781148 DOI: 10.1016/j.biopha.2021.112409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Perera S, Kelly D, O'Kane GM. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Curr Oncol 2020;27:S165-72. [PMID: 33343210 DOI: 10.3747/co.27.7159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
35 Mamur S, Gündüzer E, Yaman M. Toxicological aspect of bioinsecticide pyrethrum extract and expressions of apoptotic gene levels in human hepotacellular carcinoma HepG2 cells. Toxicol Mech Methods 2022;:1-30. [PMID: 35321623 DOI: 10.1080/15376516.2022.2057266] [Reference Citation Analysis]
36 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
37 Ryon EL, Kronenfeld JP, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Goel N, Merchant NB, Datta J. Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. J Surg Oncol 2021;123:407-15. [PMID: 33125746 DOI: 10.1002/jso.26282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80. [PMID: 28130846 DOI: 10.1002/hep.29086] [Cited by in Crossref: 1730] [Cited by in F6Publishing: 1535] [Article Influence: 432.5] [Reference Citation Analysis]
39 Liu X, Wen J, Yi H, Hou X, Yin Y, Ye G, Wu X, Jiang X. Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release. Ther Adv Med Oncol. 2020;12:1758835920910347. [PMID: 32215059 DOI: 10.1177/1758835920910347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
40 Khan F, Khan TJ, Kalamegam G, Pushparaj PN, Chaudhary A, Abuzenadah A, Kumosani T, Barbour E, Al-Qahtani M. Anti-cancer effects of Ajwa dates (Phoenix dactylifera L.) in diethylnitrosamine induced hepatocellular carcinoma in Wistar rats. BMC Complement Altern Med 2017;17:418. [PMID: 28830415 DOI: 10.1186/s12906-017-1926-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
41 Qu J, Zhao X, Ma PX, Guo B. pH-responsive self-healing injectable hydrogel based on N-carboxyethyl chitosan for hepatocellular carcinoma therapy. Acta Biomater 2017;58:168-80. [PMID: 28583902 DOI: 10.1016/j.actbio.2017.06.001] [Cited by in Crossref: 303] [Cited by in F6Publishing: 261] [Article Influence: 60.6] [Reference Citation Analysis]
42 Gao Y, Zheng QC, Xu S, Yuan Y, Cheng X, Jiang S, Kenry, Yu Q, Song Z, Liu B, Li M. Theranostic Nanodots with Aggregation-Induced Emission Characteristic for Targeted and Image-Guided Photodynamic Therapy of Hepatocellular Carcinoma. Theranostics 2019;9:1264-79. [PMID: 30867829 DOI: 10.7150/thno.29101] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 14.7] [Reference Citation Analysis]
43 Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, Davis M, de Smith AJ, Dutil J, Figueiredo JC, Fox R, Graves KD, Gomez SL, Llera A, Neuhausen SL, Newman L, Nguyen T, Palmer JR, Palmer NR, Pérez-Stable EJ, Piawah S, Rodriquez EJ, Sanabria-Salas MC, Schmit SL, Serrano-Gomez SJ, Stern MC, Weitzel J, Yang JJ, Zabaleta J, Ziv E, Fejerman L. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer 2021;124:315-32. [PMID: 32901135 DOI: 10.1038/s41416-020-01038-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 24.0] [Reference Citation Analysis]
44 Cetin M, Odabas G, Douglas LR, Duriez PJ, Balcik-Ercin P, Yalim-Camci I, Sayan AE, Yagci T. ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells. Cells 2019;8:E210. [PMID: 30832318 DOI: 10.3390/cells8030210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
45 Shi BM, Lu W, Ji K, Wang YF, Xiao S, Wang XY. Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2017; 23(20): 3713-3720 [PMID: 28611524 DOI: 10.3748/wjg.v23.i20.3713] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
46 Wang W, Wang Q, Huang DB, Sun QK, Wu SS, Zhao YJ, Jia W, Hu DS, He YF. Tumor-associated mesenchymal stem cells promote hepatocellular carcinoma metastasis via a DNM3OS/KDM6B/TIAM1 axis. Cancer Lett 2021;503:19-31. [PMID: 33472090 DOI: 10.1016/j.canlet.2021.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Bednarsch J, Czigany Z, Heise D, Joechle K, Luedde T, Heij L, Bruners P, Ulmer TF, Neumann UP, Lang SA. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbecks Arch Surg. 2021;406:75-86. [PMID: 33294952 DOI: 10.1007/s00423-020-02052-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Zheng J, Seier K, Gonen M, Balachandran VP, Kingham TP, D'Angelica MI, Allen PJ, Jarnagin WR, DeMatteo RP. Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:3706-14. [PMID: 28840521 DOI: 10.1245/s10434-017-6060-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
49 Yuan S, Dong M, Zhang H, Jiang X, Yan C, Ye R, Zhou H, Chen L, Lian H, Jin W. Ginsenoside PPD inhibit the activation of HSCs by directly targeting TGFβR1. Int J Biol Macromol 2022;194:556-62. [PMID: 34822828 DOI: 10.1016/j.ijbiomac.2021.11.098] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Kabir T, Syn NL, Tan ZZX, Tan HJ, Yen C, Koh YX, Kam JH, Teo JY, Lee SY, Cheow PC, Chow PKH, Chung AYF, Ooi LL, Chan CY, Goh BKP. Predictors of post-operative complications after surgical resection of hepatocellular carcinoma and their prognostic effects on outcome and survival: A propensity-score matched and structural equation modelling study. Eur J Surg Oncol 2020;46:1756-65. [PMID: 32345496 DOI: 10.1016/j.ejso.2020.03.219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Abdel-Rahman O, Cheung WY. The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:4763832. [PMID: 30159302 DOI: 10.1155/2018/4763832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
52 Lim C, Shinkawa H, Hasegawa K, Bhangui P, Salloum C, Gomez Gavara C, Lahat E, Omichi K, Arita J, Sakamoto Y, Compagnon P, Feray C, Kokudo N, Azoulay D. Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis. Liver Transpl 2017;23:1553-63. [DOI: 10.1002/lt.24952] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
53 Rim CH. Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma. J Liver Cancer 2021;21:113-23. [DOI: 10.17998/jlc.2021.05.26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Chu MO, Shen CH, Chang TS, Xu HW, Yen CW, Lu SN, Hung CH. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. Sci Rep 2018;8:16611. [PMID: 30413724 DOI: 10.1038/s41598-018-34543-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
55 Abdel-Rahman O. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. J Cancer Res Clin Oncol 2018;144:901-8. [PMID: 29455421 DOI: 10.1007/s00432-018-2610-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
56 Teo JY, Allen JC, Ng DCE, Abdul Latiff JB, Choo SP, Tai DW, Low ASC, Cheah FK, Chang JPE, Kam JH, Lee VTW, Chung AYF, Chan CY, Chow PKH, Goh BKP. Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma. Surgery 2018;163:1008-13. [PMID: 29306542 DOI: 10.1016/j.surg.2017.10.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
57 Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. World J Gastroenterol 2020; 26(4): 393-403 [PMID: 32063688 DOI: 10.3748/wjg.v26.i4.393] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
58 Che L, Pilo MG, Cigliano A, Latte G, Simile MM, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle. 2017;16:499-507. [PMID: 28118080 DOI: 10.1080/15384101.2017.1282586] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
59 Solanki SL, Kaur J, Gupta AM, Patkar S, Joshi R, Ambulkar RP, Patil A, Goel M. Cancer related nutritional and inflammatory markers as predictive parameters of immediate postoperative complications and long-term survival after hepatectomies. Surg Oncol 2021;37:101526. [PMID: 33582497 DOI: 10.1016/j.suronc.2021.101526] [Reference Citation Analysis]
60 Linn YL, Chua DW, Koh YX, Tan EK, Teo JY, Cheow PC, Jeyaraj PR, Chow PKH, Ooi LLPJ, Chung AYF, Chan CY, Goh BKP. Preoperative predictors of early recurrence of AJCC T4 hepatocellular carcinoma. Surg Oncol 2021;39:101671. [PMID: 34775234 DOI: 10.1016/j.suronc.2021.101671] [Reference Citation Analysis]
61 Hansmann J, Ray CE Jr. Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology. Semin Intervent Radiol 2017;34:213-9. [PMID: 28579689 DOI: 10.1055/s-0037-1602757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
62 Kierans AS, Song C, Gavlin A, Roudenko A, Lu L, Askin G, Hecht EM. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma. AJR Am J Roentgenol 2020;215:1085-92. [PMID: 32877248 DOI: 10.2214/AJR.20.22772] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
63 Chi G, Pei J, Li X, Li X, Pang H, Cui J, Wu D, Qu G, He Y. SMYD5 acts as a potential biomarker for hepatocellular carcinoma. Exp Cell Res 2022;:113076. [PMID: 35218722 DOI: 10.1016/j.yexcr.2022.113076] [Reference Citation Analysis]
64 Zhang K, Barry AE, Lamm R, Patel K, Schafer M, Dang H. The role of RNA binding proteins in hepatocellular carcinoma. Adv Drug Deliv Rev 2022;182:114114. [PMID: 35063534 DOI: 10.1016/j.addr.2022.114114] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Rakké YS, Sprengers D, Kwekkeboom J, IJzermans JNM. Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma. Ann Transl Med 2020;8:1614. [PMID: 33437813 DOI: 10.21037/atm-2020-115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Borowa-Mazgaj B, de Conti A, Tryndyak V, Steward CR, Jimenez L, Melnyk S, Seneshaw M, Mirshahi F, Rusyn I, Beland FA, Sanyal AJ, Pogribny IP. Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis. Toxicol Sci 2019;170:273-82. [PMID: 31086990 DOI: 10.1093/toxsci/kfz110] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
67 Dreval K, Tryndyak V, de Conti A, Beland FA, Pogribny IP. Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis. Front Genet 2019;10:486. [PMID: 31191608 DOI: 10.3389/fgene.2019.00486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
68 Adisa RA, Sulaimon LA, Okeke EG, Ariyo OC, Abdulkareem FB. Mitoquinol mesylate (MITOQ) attenuates diethyl nitrosamine-induced hepatocellular carcinoma through modulation of mitochondrial antioxidant defense systems. Toxicol Res . [DOI: 10.1007/s43188-021-00105-1] [Reference Citation Analysis]
69 Piscaglia F, Ogasawara S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018;7:104-119. [PMID: 29662837 DOI: 10.1159/000485471] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
70 Koh JH, Tan DJH, Ong Y, Lim WH, Ng CH, Tay PWL, Yong JN, Muthiah MD, Tan EX, Pang NQ, Kim BK, Syn N, Kow A, Goh BKP, Huang DQ. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobiliary Surg Nutr 2022;11:78-93. [PMID: 35284509 DOI: 10.21037/hbsn-21-350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Mohammed FA, Elkady AI, Syed FQ, Mirza MB, Hakeem KR, Alkarim S. Anethum graveolens (dill) – A medicinal herb induces apoptosis and cell cycle arrest in HepG2 cell line. Journal of Ethnopharmacology 2018;219:15-22. [DOI: 10.1016/j.jep.2018.03.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
72 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Goh BKP, Chua DW, Koh YX, Tan EK, Kam JH, Teo JY, Cheow PC, Jeyaraj PR, Chow PKH, Chan CY, Chung AYF, Ooi LLPJ. Continuous improvements in short and long-term outcomes after partial hepatectomy for hepatocellular carcinoma in the 21st century: Single institution experience with 1300 resections over 18 years. Surg Oncol 2021;38:101609. [PMID: 34126522 DOI: 10.1016/j.suronc.2021.101609] [Reference Citation Analysis]
74 Wei Y, Ye Z, Yuan Y, Huang Z, Wei X, Zhang T, Wan S, Tang H, He X, Song B. A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma. Liver Cancer 2020;9:414-25. [PMID: 32999868 DOI: 10.1159/000505696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
75 Debes JD, Chan AJ, Balderramo D, Kikuchi L, Gonzalez Ballerga E, Prieto JE, Tapias M, Idrovo V, Davalos MB, Cairo F. Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. Liver Int. 2018;38:136-143. [PMID: 28640517 DOI: 10.1111/liv.13502] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
76 Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
77 Khan MW, Zhao P, Khan A, Raza F, Raza SM, Sarfraz M, Chen Y, Li M, Yang T, Ma X, Xiang G. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity. Int J Nanomedicine 2019;14:3753-71. [PMID: 31239661 DOI: 10.2147/IJN.S196651] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
78 Abouzed TK, Althobaiti F, Abdelkhlek NA, Eldomany EB, Nasr NE, Sadek KM, El-Shazly SA, Kahilo KA, Dorghamm DA. Antitumor and Antioxidant Activity of S-Methyl Methionine Sulfonium Chloride against Liver Cancer Induced in Wistar Albino Rats by Diethyl Nitrosamine and Carbon Tertrachloride. Int J Environ Res Public Health 2021;18:9726. [PMID: 34574650 DOI: 10.3390/ijerph18189726] [Reference Citation Analysis]
79 Baumeister SE, Schlesinger S, Aleksandrova K, Jochem C, Jenab M, Gunter MJ, Overvad K, Tjønneland A, Boutron-ruault M, Carbonnel F, Fournier A, Kühn T, Kaaks R, Pischon T, Boeing H, Trichopoulou A, Bamia C, La Vecchia C, Masala G, Panico S, Fasanelli F, Tumino R, Grioni S, Bueno de Mesquita B, Vermeulen R, May AM, Borch KB, Oyeyemi SO, Ardanaz E, Rodríguez-barranco M, Dolores Chirlaque López M, Felez-nobrega M, Sonestedt E, Ohlsson B, Hemmingsson O, Werner M, Perez-cornago A, Ferrari P, Stepien M, Freisling H, Tsilidis KK, Ward H, Riboli E, Weiderpass E, Leitzmann MF. Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study. Journal of Hepatology 2019;70:885-92. [DOI: 10.1016/j.jhep.2018.12.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
80 Goh BKP, Syn N, Teo JY, Guo YX, Lee SY, Cheow PC, Chow PKH, Ooi LLPJ, Chung AYF, Chan CY. Perioperative Outcomes of Laparoscopic Repeat Liver Resection for Recurrent HCC: Comparison with Open Repeat Liver Resection for Recurrent HCC and Laparoscopic Resection for Primary HCC. World J Surg. 2019;43:878-885. [PMID: 30361747 DOI: 10.1007/s00268-018-4828-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
81 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
82 Liang J, Song X, Xiao Z, Chen H, Shi C, Luo L. Using IVIM-MRI and R2⁎ Mapping to Differentiate Early Stage Liver Fibrosis in a Rat Model of Radiation-Induced Liver Fibrosis. Biomed Res Int 2018;2018:4673814. [PMID: 30627558 DOI: 10.1155/2018/4673814] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
83 Sultan A, Anugwom CM, Wondifraw Z, Braimoh GA, Bane A, Debes JD. Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa. Expert Rev Gastroenterol Hepatol 2020;14:1007-11. [PMID: 32730120 DOI: 10.1080/17474124.2020.1802246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, Gwak GY. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. Int J Epidemiol 2020;49:1562-71. [PMID: 32725117 DOI: 10.1093/ije/dyaa089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
85 Kang B, Yi DY, Choe B. Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries. Front Pediatr 2022;9:809838. [DOI: 10.3389/fped.2021.809838] [Reference Citation Analysis]
86 Lim C, Bhangui P, Salloum C, Gómez-Gavara C, Lahat E, Luciani A, Compagnon P, Calderaro J, Feray C, Azoulay D. Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma. J Hepatol 2017:S0168-8278(17)32331-0. [PMID: 28989094 DOI: 10.1016/j.jhep.2017.09.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
87 Liu C, Zhong X, Li J, Xu F. Circular RNA circVAPA Promotes Cell Proliferation in Hepatocellular Carcinoma. Hum Gene Ther Clin Dev. 2019;30:152-159. [PMID: 31368365 DOI: 10.1089/humc.2019.079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
88 Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 3980-3999 [PMID: 30254403 DOI: 10.3748/wjg.v24.i35.3980] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
89 Le Linn Y, Guo Y, Koh YX, Chow PKH, Chan CY, Chung AYF, Ooi LLPJ, Goh BKP. Preoperative Predictors of Futile Resection of Intraabdominal Extrahepatic Metastases from Hepatocellular Carcinoma. World J Surg 2021;45:1144-51. [PMID: 33521877 DOI: 10.1007/s00268-020-05907-2] [Reference Citation Analysis]
90 Chen F, Zhong Z, Tan HY, Guo W, Zhang C, Cheng CS, Wang N, Ren J, Feng Y. Suppression of lncRNA MALAT1 by betulinic acid inhibits hepatocellular carcinoma progression by targeting IAPs via miR-22-3p. Clin Transl Med 2020;10:e190. [PMID: 33135336 DOI: 10.1002/ctm2.190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
91 Kiefer RM, Hunt SJ, Pulido S, Pickup S, Furth EE, Soulen MC, Nadolski GJ, Gade TP. Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization. J Vasc Interv Radiol 2017;28:1043-1050.e2. [PMID: 28495453 DOI: 10.1016/j.jvir.2017.03.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
92 Beumer BR, Takagi K, Vervoort B, Buettner S, Umeda Y, Yagi T, Fujiwara T, Steyerberg EW, IJzermans JNM. Prediction of Early Recurrence After Surgery for Liver Tumor (ERASL): An International Validation of the ERASL Risk Models. Ann Surg Oncol 2021. [PMID: 34235600 DOI: 10.1245/s10434-021-10235-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol 2021;17:2759-68. [PMID: 33832339 DOI: 10.2217/fon-2021-0242] [Reference Citation Analysis]
94 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22:141-150. [PMID: 30455585 DOI: 10.5114/wo.2018.78941] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 15.8] [Reference Citation Analysis]
96 Byun J, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI. Hepatol Int 2020;14:534-43. [PMID: 32314171 DOI: 10.1007/s12072-020-10040-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
97 Bednarsch J, Czigany Z, Heij LR, Amygdalos I, Heise D, Bruners P, Ulmer TF, Neumann UP, Lang SA. The role of re-resection in recurrent hepatocellular carcinoma. Langenbecks Arch Surg. [DOI: 10.1007/s00423-022-02545-1] [Reference Citation Analysis]
98 Liu S, Yao X, Zhang D, Sheng J, Wen X, Wang Q, Chen G, Li Z, Du Z, Zhang X. Analysis of Transcription Factor-Related Regulatory Networks Based on Bioinformatics Analysis and Validation in Hepatocellular Carcinoma. Biomed Res Int. 2018;2018:1431396. [PMID: 30228980 DOI: 10.1155/2018/1431396] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
99 Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019;25:245-63. [PMID: 30759967 DOI: 10.3350/cmh.2018.0090] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 27.3] [Reference Citation Analysis]
100 Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz CD, Kudo M. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 2019;71:543-552. [PMID: 31176752 DOI: 10.1016/j.jhep.2019.05.014] [Cited by in Crossref: 67] [Cited by in F6Publishing: 79] [Article Influence: 22.3] [Reference Citation Analysis]
101 Lan H, Lin G, Zhong W. A meta-analysis of the added value of diffusion weighted imaging in combination with contrast-enhanced magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma lesser or equal to 2 cm. Oncol Lett 2020;20:2739-48. [PMID: 32782590 DOI: 10.3892/ol.2020.11805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
102 Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing Epidemiology of Hepatocellular Carcinoma in Asia. Liver Int 2022. [PMID: 35319165 DOI: 10.1111/liv.15251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, Yu ML, Tanaka Y, Nguyen MH. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. Hepatol Commun. 2019;3:493-503. [PMID: 30976740 DOI: 10.1002/hep4.1321] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
104 Wong WG, Perez Holguin RA, Tarren AY, Shen C, Vining C, Peng JS, Dixon ME. Albumin-bilirubin score is superior to platelet-albumin-bilirubin score and model for end-state liver disease sodium for predicting posthepatectomy liver failure. J Surg Oncol 2022. [PMID: 35726364 DOI: 10.1002/jso.26981] [Reference Citation Analysis]
105 Baumeister SE, Leitzmann MF, Linseisen J, Schlesinger S. Physical Activity and the Risk of Liver Cancer: A Systematic Review and Meta-Analysis of Prospective Studies and a Bias Analysis. J Natl Cancer Inst 2019;111:1142-51. [PMID: 31168582 DOI: 10.1093/jnci/djz111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
106 Wong L, Bozhilov K, Hernandez B, Kwee S, Chan O, Ellis L, LeMarchand L. Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio. Clin Mol Hepatol. 2019;25:305-316. [PMID: 31001964 DOI: 10.3350/cmh.2019.0004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
107 Benkheil M, Van Haele M, Roskams T, Laporte M, Noppen S, Abbasi K, Delang L, Neyts J, Liekens S. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer. Exp Cell Res. 2018;372:168-177. [PMID: 30287142 DOI: 10.1016/j.yexcr.2018.09.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
108 Zheng J, Chou JF, Gönen M, Vachharajani N, Chapman WC, Majella Doyle MB, Turcotte S, Vandenbroucke-Menu F, Lapointe R, Buettner S, Groot Koerkamp B, Ijzermans JNM, Chan CY, Goh BKP, Teo JY, Kam JH, Jeyaraj PR, Cheow PC, Chung AYF, Chow PKH, Ooi LLPJ, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR, Lee SY. Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Ann Surg 2017;266:693-701. [PMID: 28650354 DOI: 10.1097/SLA.0000000000002360] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
109 Srinivasa S, Hughes M, Azodo IA, Adair A, Ravindran R, Harrison E, Wigmore SJ. Laparoscopic liver resection in cirrhotics: feasibility and short-term outcomes compared to non-cirrhotics. ANZ J Surg 2020;90:1104-7. [PMID: 32072750 DOI: 10.1111/ans.15745] [Reference Citation Analysis]
110 Kim TH, Yoon JH, Lee JM. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. Korean J Radiol 2019;20:863-79. [PMID: 31132813 DOI: 10.3348/kjr.2018.0450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
111 Rim CH, Cheng J, Huang W, Kimura T, Lee V, Zeng Z, Seong J. An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy and Oncology 2020;148:73-81. [DOI: 10.1016/j.radonc.2020.03.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
112 Zhang F, Ma X, Li H, Guo G, Li P, Li H, Gu L, Li X, Chen L, Zhang X. The predictive and prognostic values of serum amino acid levels for clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2017;35:392-400. [DOI: 10.1016/j.urolonc.2017.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
113 Ray EM, Sanoff HK. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. J Hepatocell Carcinoma 2017;4:131-8. [PMID: 29184856 DOI: 10.2147/JHC.S124366] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
114 Liao Y, Wei R, Yao R, Qin L, Li J, Yu J, Liao W. AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study. BMC Surg 2021;21:72. [PMID: 33536005 DOI: 10.1186/s12893-020-01037-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Huang LH, Hsieh TM, Huang CY, Liu YW, Wu SC, Chien PC, Hsieh CH. Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations. Genes (Basel) 2021;12:1274. [PMID: 34440448 DOI: 10.3390/genes12081274] [Reference Citation Analysis]
116 Muhammad Irham L, Chou WH, Wang YS, Adikusuma W, Sung-Ching Wong H, Aryani Perwitasari D, Huang WC, Chen BK, Yang HI, Chang WC. Evaluation for the Genetic Association between Store-Operated Calcium Influx Pathway (STIM1 and ORAI1) and Human Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection. Biology (Basel) 2020;9:E388. [PMID: 33182378 DOI: 10.3390/biology9110388] [Reference Citation Analysis]
117 Liu X, Wang Z, Chen Z, Liu L, Ma L, Dong L, Zhang Z, Zhang S, Yang L, Shi J, Fan J, Wang X, Gao Q. Efficacy and Safety of Transcatheter Arterial Chemoembolization and Transcatheter Arterial Chemotherapy Infusion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Oncol Res 2018;26:231-9. [PMID: 28911342 DOI: 10.3727/096504017X15051752095738] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
118 Sunagawa Y, Yamada S, Sonohara F, Kurimoto K, Tanaka N, Suzuki Y, Inokawa Y, Takami H, Hayashi M, Kanda M, Tanaka C, Nakayama G, Koike M, Kodera Y. Genome-wide identification and characterization of circular RNA in resected hepatocellular carcinoma and background liver tissue. Sci Rep 2021;11:6016. [PMID: 33727578 DOI: 10.1038/s41598-021-85237-y] [Reference Citation Analysis]
119 Lu H, Zhu Q. Identification of Key Biological Processes, Pathways, Networks, and Genes with Potential Prognostic Values in Hepatocellular Carcinoma Using a Bioinformatics Approach. Cancer Biother Radiopharm 2020. [PMID: 32598174 DOI: 10.1089/cbr.2019.3327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
120 Lee SK, Jang JW, Nam H, Sung PS, Kim HY, Kwon JH, Lee SW, Song DS, Kim CW, Song MJ, Choi HJ, You YK, Bae SH, Choi JY, Yoon SK. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatol Int 2021;15:137-45. [PMID: 33496932 DOI: 10.1007/s12072-020-10131-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Scheiner B, Pinter M. Reply to: “The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations”. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.030] [Reference Citation Analysis]
122 Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers (Basel) 2021;13:1673. [PMID: 33918125 DOI: 10.3390/cancers13071673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Barry AE, Baldeosingh R, Lamm R, Patel K, Zhang K, Dominguez DA, Kirton KJ, Shah AP, Dang H. Hepatic Stellate Cells and Hepatocarcinogenesis. Front Cell Dev Biol 2020;8:709. [PMID: 32850829 DOI: 10.3389/fcell.2020.00709] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
124 Chen S, Du Y, Xu B, Li Q, Yang L, Jiang Z, Zeng Z, Chen L. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance. Oncogene 2021;40:3378-93. [PMID: 33875785 DOI: 10.1038/s41388-021-01780-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Kim T, Woo S, Han S, Suh CH, Lee DH, Lee JM. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis. Eur Radiol 2020;30:1624-33. [DOI: 10.1007/s00330-019-06499-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Morishita A, Tani J, Nomura T, Takuma K, Nakahara M, Oura K, Tadokoro T, Fujita K, Shi T, Yamana H, Matsui T, Takata T, Sanomura T, Nishiyama Y, Himoto T, Tomonari T, Moriya A, Senoo T, Takaguchi K, Masaki T. Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study. Cancers (Basel) 2021;13:4605. [PMID: 34572832 DOI: 10.3390/cancers13184605] [Reference Citation Analysis]
127 Zheng YL, Li L, Jia YX, Zhang BZ, Li JC, Zhu YH, Li MQ, He JZ, Zeng TT, Ban XJ, Yuan YF, Li Y, Guan XY. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway. Theranostics 2019;9:796-810. [PMID: 30809309 DOI: 10.7150/thno.28992] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 18.7] [Reference Citation Analysis]
128 Kabir T, Syn N, Ramkumar M, Yeo EYJ, Teo JY, Koh YX, Lee SY, Cheow PC, Chow PKH, Chung AYF, Ooi LL, Chan CY, Goh BKP. Effect of surgical delay on survival outcomes in patients undergoing curative resection for primary hepatocellular carcinoma: Inverse probability of treatment weighting using propensity scores and propensity score adjustment. Surgery 2020;167:417-24. [PMID: 31677800 DOI: 10.1016/j.surg.2019.09.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
129 Salman S, Meyers DJ, Wicks EE, Lee SN, Datan E, Thomas AM, Anders NM, Hwang Y, Lyu Y, Yang Y, Jackson W, Dordai D, Rudek MA, Semenza GL. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. Journal of Clinical Investigation 2022;132:e156774. [DOI: 10.1172/jci156774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Mikami K, Endo T, Sawada N, Igarashi GO, Kimura M, Sakuraba H, Fukuda S. Inhibition of Systemic Hyaluronan Synthesis Exacerbates Murine Hepatic Carcinogenesis. In Vivo 2018;32:273-8. [PMID: 29475909 DOI: 10.21873/invivo.11234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
131 Rodríguez MM, Fiore E, Bayo J, Atorrasagasti C, García M, Onorato A, Domínguez L, Malvicini M, Mazzolini G. 4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12. Mol Ther 2018;26:2738-50. [PMID: 30301668 DOI: 10.1016/j.ymthe.2018.09.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
132 Ng KYY, Wong LWJ, Ang AJS, Tan SH, Choo SP, Tai DW, Lee JJX. Real‐world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. Asia‐Pac J Clin Oncol 2021;17. [DOI: 10.1111/ajco.13454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
133 Kabir T, Tan ZZ, Syn NL, Wu E, Lin JD, Zhao JJ, Tan AYH, Hui Y, Kam JH, Goh BKP. Laparoscopic versus open resection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Br J Surg 2021:znab376. [PMID: 34757385 DOI: 10.1093/bjs/znab376] [Reference Citation Analysis]
134 Linn YL, Chee MY, Koh YX, Teo JY, Cheow PC, Chow PKH, Chan CY, Chung AYF, Ooi LLPJ, Goh BKP. Actual 10-year survivors and 10-year recurrence free survivors after primary liver resection for hepatocellular carcinoma in the 21st century: A single institution contemporary experience. J Surg Oncol 2021;123:214-21. [PMID: 33095920 DOI: 10.1002/jso.26259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Luong AB, Do HQ, Tarchi P, Bonazza D, Bottin C, Cabral LKD, Tran LDC, Doan TPT, Crocè LS, Pham HLT, Tiribelli C, Sukowati CHC. The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations. Cells 2020;9:E2672. [PMID: 33322687 DOI: 10.3390/cells9122672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Lee HA, Rim CH. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. J Hepatocell Carcinoma 2020;7:435-46. [PMID: 33376712 DOI: 10.2147/JHC.S285357] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Al-Naamani K, Al-Hashami Z, Al-Siyabi O, Al-Moundri M, Al-Bahrani B, Al-Sinani S, Al-Zakwani I, Omar H, Al-Busafi SA, Al-Zuhaibi H, AlMamari A, Kamath BR, Al-Kalbani A, Burney IA. Hepatocellular Carcinoma in Oman: An analysis of 284 cases. Sultan Qaboos Univ Med J 2020;20:e316-22. [PMID: 33110647 DOI: 10.18295/squmj.2020.20.03.011] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Obi S, Sato T, Sato S. Immune checkpoint inhibitor in liver cancer-unique regional differences. Ann Transl Med 2020;8:1336. [PMID: 33313081 DOI: 10.21037/atm-20-3378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
139 Pan W, Luo Q, Yan X, Yuan L, Yi H, Zhang L, Li B, Zhang Y, Sun J, Qiu MZ, Yang DJ. A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity. Biochem Pharmacol 2018;154:127-35. [PMID: 29679556 DOI: 10.1016/j.bcp.2018.04.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
140 Hasan S, Abel S, Uemura T, Verma V, Koay EJ, Herman J, Thai N, Kirichenko A. Liver transplant mortality and morbidity following preoperative radiotherapy for hepatocellular carcinoma. HPB 2020;22:770-8. [DOI: 10.1016/j.hpb.2019.10.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
141 Zhang Y, Zhou Z, Liu G. Factors predicting early recurrence after surgical resection of hepatocellular carcinoma. Journal of Hepatology 2019;70:571-2. [DOI: 10.1016/j.jhep.2018.10.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
142 Al Jarroudi O, Chaabouni H, Ulusakarya A, Almohamad W, Gumus Y, Goldschmidt E, Afqir S, Morère JF. Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience. Clin Case Rep 2021;9:2162-7. [PMID: 33936657 DOI: 10.1002/ccr3.3970] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]